Strong first-half 2014 sales and earnings growth for Actelion

22 July 2014
2019_biotech_test_vial_discovery_big

Switzerland’s Actelion (SIX: ATLN), Europe’s largest biotech company, this morning posted a strong set of financial results for the first half of 2014, with product sales of 993 million Swiss francs ($1.03 billion), up 17% at constant exchange rates (CER), and up 11% excluding US rebate reversals.

Core operating income leapt 27% (35% at CER) to 421 million francs. US generally-accepted accounting principles (GAPP) earnings per share (fully diluted) rocketed 109% (124% at CER) to 3.62 francs and core EPS was up 39% (48% at CER) to 3.25 francs. Core earnings per share for the second quarter alone were 233 million francs, well ahead of the 171 million francs average forecast in a Reuters poll. Actelion’s shares rose 2.55% to 112.40 francs in early trading.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Biotechnology